577 related articles for article (PubMed ID: 29535126)
21. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
22. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
[TBL] [Abstract][Full Text] [Related]
23. Selecting short length nucleic acids localized in exosomes improves plasma
Kim Y; Shin S; Kim B; Lee KA
Cancer Cell Int; 2019; 19():251. PubMed ID: 31582907
[TBL] [Abstract][Full Text] [Related]
24. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
[TBL] [Abstract][Full Text] [Related]
25. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
27. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure.
Zhou J; Zhao C; Zhao J; Wang Q; Chu X; Li J; Zhou F; Ren S; Li X; Su C; Zhou C
Thorac Cancer; 2019 Apr; 10(4):957-965. PubMed ID: 30887673
[TBL] [Abstract][Full Text] [Related]
28. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
Qian X; Liu J; Sun Y; Wang M; Lei H; Luo G; Liu X; Xiong C; Liu D; Liu J; Tang Y
Oncotarget; 2016 May; 7(20):29154-65. PubMed ID: 27081078
[TBL] [Abstract][Full Text] [Related]
29. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
[TBL] [Abstract][Full Text] [Related]
30. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
[TBL] [Abstract][Full Text] [Related]
31. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
32. Discrimination of Germline
Hu Y; Alden RS; Odegaard JI; Fairclough SR; Chen R; Heng J; Feeney N; Nagy RJ; Shah J; Ulrich B; Gutierrez M; Lanman RB; Garber JE; Paweletz CP; Oxnard GR
Clin Cancer Res; 2017 Dec; 23(23):7351-7359. PubMed ID: 28947568
[No Abstract] [Full Text] [Related]
33. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
Kogure Y; Shigematsu F; Oki M; Saka H
In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
[TBL] [Abstract][Full Text] [Related]
34. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
35. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.
Mistry R; Patil A
Indian J Cancer; 2017 Dec; 54(Supplement):S65-S66. PubMed ID: 29292710
[TBL] [Abstract][Full Text] [Related]
36. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
[TBL] [Abstract][Full Text] [Related]
37. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
[TBL] [Abstract][Full Text] [Related]
38. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
[TBL] [Abstract][Full Text] [Related]
39. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
[TBL] [Abstract][Full Text] [Related]
40. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
Reckamp KL; Melnikova VO; Karlovich C; Sequist LV; Camidge DR; Wakelee H; Perol M; Oxnard GR; Kosco K; Croucher P; Samuelsz E; Vibat CR; Guerrero S; Geis J; Berz D; Mann E; Matheny S; Rolfe L; Raponi M; Erlander MG; Gadgeel S
J Thorac Oncol; 2016 Oct; 11(10):1690-700. PubMed ID: 27468937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
